Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 17092

Sort by

Sort Order Select

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

Gene therapy for sickle cell disease: moving from the bench to the bedside

Allistair A. Abraham, John F. Tisdale

Blood (2021) 138 (11): 932–941.

https://doi.org/10.1182/blood.2019003776

Published: 2021

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

Blood (2021) 138 (7): 557–570.

https://doi.org/10.1182/blood.2020009845

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Fitness for intensive chemotherapy: a continuing conundrum

Andrew H. Wei

Blood (2021) 138 (5): 356–358.

https://doi.org/10.1182/blood.2021011361

Published: 2021

Journal Articles

Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment

Min Xiao, Wuju Zhang, Wen Liu, Linlin Mao, Jincheng Yang, Le Hu, Sheng Zhang, Yaling Zheng, Anling Liu, Qiancheng Song, Yuhua Li, Guozhi Xiao, Zhipeng Zou, Xiaochun Bai

Blood (2021) 137 (25): 3533–3547.

https://doi.org/10.1182/blood.2020007731

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2021) 137 (19): 2704–2707.

https://doi.org/10.1182/blood.2020008119

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Taking aim at IDH in fitter patients with AML

Andrew H. Wei, Naval Daver

Blood (2021) 137 (13): 1706–1707.

https://doi.org/10.1182/blood.2020009361

Published: 2021

Journal Articles

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Blood (2021) 137 (13): 1792–1803.

https://doi.org/10.1182/blood.2020007233

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Blood (2021) 137 (11): 1527–1537.

https://doi.org/10.1182/blood.2020006923

Published: 2021

Includes: Supplemental data

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter

Blood (2021) 137 (10): 1318–1326.

https://doi.org/10.1182/blood.2020007400

Published: 2021

Includes: Supplemental data

Journal Articles

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Fieke W. Hoff, Anneke D. van Dijk, Yihua Qiu, Peter P. Ruvolo, Robert B. Gerbing, Amanda R. Leonti, Gaye N. Jenkins, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Eveline S. J. M. de Bont, Sophia W. M. Bruggeman, Steven M. Kornblau, Terzah M. Horton

Blood (2021) 137 (8): 1050–1060.

https://doi.org/10.1182/blood.2020005208

Published: 2021

Includes: Supplemental data

Journal Articles

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Kimihito C. Kawabata, Hongliang Zong, Cem Meydan, Sarah Wyman, Bas J. Wouters, Mayumi Sugita, Srinjoy Goswami, Michael Albert, Winnie Yip, Gail J. Roboz, Zhengming Chen, Ruud Delwel, Martin Carroll, Christopher E. Mason, Ari Melnick, Monica L. Guzman

Blood (2021) 137 (6): 812–825.

https://doi.org/10.1182/blood.2019001745

Published: 2021

Includes: Supplemental data

NARROW

How I treat pediatric acute myeloid leukemia

Gene therapy for sickle cell disease: moving from the bench to the bedside

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Fitness for intensive chemotherapy: a continuing conundrum

Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Taking aim at IDH in fitter patients with AML

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Heat shock factor 1 (HSF1-pSer 326 ) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only